These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 38925680)

  • 21. R409K mutation prevents acid-induced aggregation of human IgG4.
    Namisaki H; Saito S; Hiraishi K; Haba T; Tanaka Y; Yoshida H; Iida S; Takahashi N
    PLoS One; 2020; 15(3):e0229027. PubMed ID: 32182240
    [TBL] [Abstract][Full Text] [Related]  

  • 22. IgG antibodies to cyclic citrullinated peptides exhibit profiles specific in terms of IgG subclasses, Fc-glycans and a fab-Peptide sequence.
    Lundström SL; Fernandes-Cerqueira C; Ytterberg AJ; Ossipova E; Hensvold AH; Jakobsson PJ; Malmström V; Catrina AI; Klareskog L; Lundberg K; Zubarev RA
    PLoS One; 2014; 9(11):e113924. PubMed ID: 25426976
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Plant-derived Durvalumab variants show efficient PD-1/PD-L1 blockade and therapeutically favourable FcR binding.
    Izadi S; Gumpelmair S; Coelho P; Duarte HO; Gomes J; Leitner J; Kunnummel V; Mach L; Reis CA; Steinberger P; Castilho A
    Plant Biotechnol J; 2024 May; 22(5):1224-1237. PubMed ID: 38050338
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fc glycoengineering of a PD-L1 antibody harnesses Fcγ receptors for increased antitumor efficacy.
    Cohen Saban N; Yalin A; Landsberger T; Salomon R; Alva A; Feferman T; Amit I; Dahan R
    Sci Immunol; 2023 Mar; 8(81):eadd8005. PubMed ID: 36867679
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel oncolytic adenovirus expressing enhanced cross-hybrid IgGA Fc PD-L1 inhibitor activates multiple immune effector populations leading to enhanced tumor killing in vitro, in vivo and with patient-derived tumor organoids.
    Hamdan F; Ylösmäki E; Chiaro J; Giannoula Y; Long M; Fusciello M; Feola S; Martins B; Feodoroff M; Antignani G; Russo S; Kari O; Lee M; Järvinen P; Nisen H; Kreutzman A; Leusen J; Mustjoki S; McWilliams TG; Grönholm M; Cerullo V
    J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34362830
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A monoclonal antibody against hinge-cleaved IgG restores effector function to proteolytically-inactivated IgGs in vitro and in vivo.
    Brezski RJ; Kinder M; Grugan KD; Soring KL; Carton J; Greenplate AR; Petley T; Capaldi D; Brosnan K; Emmell E; Watson S; Jordan RE
    MAbs; 2014; 6(5):1265-73. PubMed ID: 25517311
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comprehensive Analysis of the Therapeutic IgG4 Antibody Pembrolizumab: Hinge Modification Blocks Half Molecule Exchange In Vitro and In Vivo.
    Yang X; Wang F; Zhang Y; Wang L; Antonenko S; Zhang S; Zhang YW; Tabrizifard M; Ermakov G; Wiswell D; Beaumont M; Liu L; Richardson D; Shameem M; Ambrogelly A
    J Pharm Sci; 2015 Dec; 104(12):4002-4014. PubMed ID: 26308749
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Structural basis of HLX10 PD-1 receptor recognition, a promising anti-PD-1 antibody clinical candidate for cancer immunotherapy.
    Issafras H; Fan S; Tseng CL; Cheng Y; Lin P; Xiao L; Huang YJ; Tu CH; Hsiao YC; Li M; Chen YH; Ho CH; Li O; Wang Y; Chen S; Ji Z; Zhang E; Mao YT; Liu E; Yang S; Jiang W
    PLoS One; 2021; 16(12):e0257972. PubMed ID: 34972111
    [TBL] [Abstract][Full Text] [Related]  

  • 29. IgG4 antibodies from patients with asymptomatic bancroftian filariasis inhibit the binding of IgG1 and IgG2 to C1q in a Fc-Fc-dependent mechanism.
    Prodjinotho UF; Hoerauf A; Adjobimey T
    Parasitol Res; 2019 Oct; 118(10):2957-2968. PubMed ID: 31485865
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Full-length recombinant antibodies from
    Rashid MH
    MAbs; 2022; 14(1):2111748. PubMed ID: 36018829
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fc Engineering Approaches to Enhance the Agonism and Effector Functions of an Anti-OX40 Antibody.
    Zhang D; Goldberg MV; Chiu ML
    J Biol Chem; 2016 Dec; 291(53):27134-27146. PubMed ID: 27856634
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interaction of K lymphocytes with myeloma proteins of different IgG subclasses.
    Spiegelberg HL; Perlmann H; Perlmann P
    J Immunol; 1976 Nov; 117(5 Pt 1):1464-71. PubMed ID: 1002986
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Human IgG1 monoclonal antibody against human collagen 17 noncollagenous 16A domain induces blisters via complement activation in experimental bullous pemphigoid model.
    Li Q; Ujiie H; Shibaki A; Wang G; Moriuchi R; Qiao HJ; Morioka H; Shinkuma S; Natsuga K; Long HA; Nishie W; Shimizu H
    J Immunol; 2010 Dec; 185(12):7746-55. PubMed ID: 21076071
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Distinct effector functions mediated by Fc regions of bovine IgG subclasses and their interaction with Fc gamma receptors.
    Noble A; Paudyal B; Schwartz JC; Mwangi W; Munir D; Tchilian E; Hammond JA; Graham SP
    Front Immunol; 2023; 14():1286903. PubMed ID: 38077405
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Development of a recombinant human IL-15·sIL-15Rα/Fc superagonist with improved half-life and its antitumor activity alone or in combination with PD-1 blockade in mouse model.
    Zhao M; Luo M; Xie Y; Jiang H; Cagliero C; Li N; Ye H; Wu M; Hao S; Sun T; Yang H; Zhang M; Lin T; Lu H; Zhu J
    Biomed Pharmacother; 2019 Apr; 112():108677. PubMed ID: 30798123
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Characterization of a humanized IgG4 anti-HLA-DR monoclonal antibody that lacks effector cell functions but retains direct antilymphoma activity and increases the potency of rituximab.
    Stein R; Qu Z; Chen S; Solis D; Hansen HJ; Goldenberg DM
    Blood; 2006 Oct; 108(8):2736-44. PubMed ID: 16778139
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rationally targeted anti-VISTA antibody that blockades the C-C' loop region can reverse VISTA immune suppression and remodel the immune microenvironment to potently inhibit tumor growth in an Fc independent manner.
    Thakkar D; Paliwal S; Dharmadhikari B; Guan S; Liu L; Kar S; Tulsian NK; Gruber JJ; DiMascio L; Paszkiewicz KH; Ingram PJ; D Boyd-Kirkup J
    J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35131861
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Human monoclonal anti-D antibodies. II. The relationship between IgG subclass, Gm allotype and Fc mediated function.
    Kumpel BM; Wiener E; Urbaniak SJ; Bradley BA
    Br J Haematol; 1989 Mar; 71(3):415-20. PubMed ID: 2539182
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antibody C region influences TGN1412-like functional activity in vitro.
    Ball C; Fox B; Hufton S; Sharp G; Poole S; Stebbings R; Eastwood D; Findlay L; Parren PW; Thorpe R; Bristow A; Thorpe SJ
    J Immunol; 2012 Dec; 189(12):5831-40. PubMed ID: 23150712
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An Fc engineering approach that modulates antibody-dependent cytokine release without altering cell-killing functions.
    Kinder M; Greenplate AR; Strohl WR; Jordan RE; Brezski RJ
    MAbs; 2015; 7(3):494-504. PubMed ID: 25933349
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.